Bladder Cancer

What Sets Us Apart

At NYU Langone’s Laura and Isaac Perlmutter Cancer Center, urologic surgeons, medical oncologists, imaging specialists, and urologic pathologists work together to diagnose and treat people who have bladder cancer.

With one of the largest bladder cancer research programs in the United States, NYU Langone physicians draw upon the latest research to offer the newest approaches to care. These include the most modern diagnostic imaging techniques, such as PET/MRI scans, and robotic-assisted surgery, which is associated with shorter recovery times.

VISIONARY THINKING AND COMPASSIONATE CARE
 

At NYU Langone’s Perlmutter Cancer Center, a National Cancer Institute-designated cancer center, we personalize the care of every patient.More About Perlmutter Cancer Center

CLINICAL TRIALS and Research Studies
 

Our teams of physicians and scientists work together across multiple disciplines to bring our patients the most innovative clinical trials.Find a Clinical Trial

NYU Langone physicians are leaders in the development of the most sophisticated treatment for people with bladder cancer, and can provide access to clinical trials in which new approaches to care are being studied. Our specialists also provide an array of support services throughout treatment.

Clinical Trials and Research Studies

Phase 1

A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB (MSB0010718C) IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES

Learn More

Phase 1

An Open-Label Randomised Multi-Drug Biomarker-Directed Multi-Centre Multi-arm Phase 1b Study in patients with Muscle Invasive Bladder Cancer (MIBC) who have progressed on prior treatment (BISCAY)

Learn More

Phase 2

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Learn More

Phase 2

A Phase II Trial of MK3475 in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder Sparing Treatment for Muscle-Invasive Urothelial Cancer of the Bladder

Learn More